Endothelial Cell PAI-1 Production — Modulation by Malignant Cells in vitro

  • Lu Wei Zhen
  • Meng Chun Ling
  • Nicholas Wickham
Part of the NATO ASI Series book series (NSSA, volume 294)

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a single chain glycoprotein of approximately 50,000 Daltons which is synthesized by endothelial cells and hepatocytes. It is one of the many factors that endothelial cells (EC) secrete which are involved intimately in the maintenance of the haemostatic balance. In malignant states, especially those with widespread metastasis, this balance is frequently upset with a resulting increase in thromboembolic events. There is not one single easily identifiable pattern of changes that accounts for this increased risk, but disruption of the fibrinolytic system, in particular an increase in circulating PAI-1 concentration, is a common finding in patients with cancer. We wanted to assess the degree to which this might be due to an effect of malignant cells upon EC PAI-1 production.

Keywords

Human Umbilical Vein Endothelial Cell Human Thrombin Thrombin Stimulation Identifiable Pattern Pool Human Plasma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Declerck PJ, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71(1):220, 1988.PubMedGoogle Scholar
  2. 2.
    Nand S, et al. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 5(12): 1998, 1987.PubMedGoogle Scholar
  3. 3.
    Zurbon KH, et al. Investigations of coagulation of system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin’s lymphomas. Oncology 47(5): 376, 1990.CrossRefGoogle Scholar
  4. 4.
    Mannucci PM, et al. Changes in fibrinolysis in patients with localized tumors. Eur J Cancer 26(2): 83, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    ATCC Cell Lines & Hybridomas, 8th Edition 227, 1994, ATCC HB-8065, (Reference: Nature (Lond.)282:615, 1979.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Lu Wei Zhen
    • 1
  • Meng Chun Ling
    • 1
  • Nicholas Wickham
    • 1
  1. 1.Department of Clinical Oncology, The Sir Yue Kong-Pao Cancer Centre, Prince of Wales HospitalChinese University of Hong KongShatin, N.T.China

Personalised recommendations